FONT-SIZE Plus   Neg

Aduro BioTech Acquires GVAX Assets From BioSante Pharma - Quick Facts

Aduro BioTech Inc. announced the acquisition of all GVAX assets from BioSante Pharmaceuticals Inc. (BPAX), including intellectual property and cell lines.

Aduro previously licensed two GVAX vaccines, GVAX Pancreas and GVAX Prostate, for use in combination with its Listeria-based vaccines.

Aduro said that the new acquisition covers all uses and includes additional vaccines for multiple myeloma and breast and colon cancer and assumes rights to the existing license agreement for GVAX Melanoma.

Under its purchase agreement with BioSante, Aduro paid $1 million upfront and has committed to additional milestone and royalty payments after commercialization of GVAX product(s).

GVAX vaccines are based on human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Flying is the passion for British aviatrix Tracey Curtis Taylor, and she is now on a solo flight to cross three continents and 23 countries in her own vintage open cockpit biplane. She has already crossed half of her journey from U.K. to Australia with a target to cover 13 thousand miles. Sony Computer Entertainment Inc. Wednesday revealed that its popular PlayStation4 computer entertainment system has achieved total sales of more than 30.2 million units worldwide in a period of two years. The PS4 system is currently available in 124 countries. Cement giant LafargeHolcim (HCMLY.PK, HCMLF.PK), formed by the combination of French Lafarge and Swiss peer Holcim, Wednesday said its sales declined for the third quarter as well as nine months.
comments powered by Disqus
Trade BPAX now with 
Follow RTT